Emmaus Life Sciences, Inc. (EMMA) Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the United States and internationally. The company's flagship product is Endari, an L-glutamine oral powder designed to mitigate the acute complications associated with sickle cell disease in patients aged five and above, covering both pediatric and adult populations. Furthermore, Emmaus maintains a collaborative arrangement with Kainos Medicine, Inc. for the preclinical advancement of Kainos' proprietary IRAK4 inhibitor, KM10544, which is being explored as a potential anti-cancer therapeutic. Established in 2000 as Emmaus Holdings, Inc., the organization rebranded to Emmaus Life Sciences, Inc. in September 2011 and operates from its headquarters in Torrance, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Emmaus Life Sciences, Inc. OTC:EMMA Healthcare · Biotechnology
All Press Release SEC Filings News
Press Release ⚠ 2
Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer
Emmaus entered into an exclusive option agreement with Cedars-Sinai to evaluate L-glutamine oral powder in combination with chemotherapy for pancreatic cancer.
The agreement builds on results from the GlutaPanc trial recently published in Nature Cancer, targeting Pancreatic Ductal Adenocarcinoma.
CEO Willis Lee emphasized the move as a step to explore new treatment options beyond the company's established sickle cell disease focus.
• 1mo ago AI analysis › Press Release ● Major ⚠ 3
Emmaus Life Sciences Reports Quarterly Financial Results
Emmaus Life Sciences reported Q3 revenue of $6.3 million, up 124% year-over-year, driven by revenue recognition from its licensing deal with NeoImmuneTech.
The company swung to a net income of $1.3 million, or $0.02 per share, compared to a net loss of $1.1 million in the same period last year, aided by reduced operating expenses.
Despite the quarterly profitability, the company ended the period with $2.8 million in cash and a significant stockholders' deficit.
• 2mo ago AI analysis › Press Release ⚠ 4
Emmaus Life Sciences Reports Quarterly Financial Results
Emmaus Life Sciences reported Q1 2026 net revenues of $1.98 million, an 18% decline year-over-year driven by a 33% drop in U.S. sales due to generic L-Glutamine competition.
The company posted a net loss of $3.3 million ($0.05 per share), widening from $2.3 million in the prior year, primarily due to higher other expenses including interest and derivative fair value changes.
Cash reserves stood at $1.1 million at quarter-end, down from $2.1 million, while the balance sheet reflects a stockholders' deficit of $67.9 million against $70.6 million in current liabilities, highlighting significant liquidity pressure.
• 5mo ago AI analysis › SEC Filing ● Major ⚠ 6
EMMA: 10-Q · periodic report
Emmaus Life Sciences reported a net loss of $3.3 million for Q1 2026, driven by a 18% decline in revenue to $2.0 million as generic competition from ANI Pharmaceuticals erodes sales of its sole product, Endari. The company faces severe liquidity constraints, holding only $1.1 million in cash against a $64.5 million working capital deficit, leading management to disclose substantial doubt about its ability to continue as a going concern.
To address immediate cash needs, Emmaus entered into a Sale of Future Receipts Agreement with Breeze Funding, selling $1.69 million of future receivables for $1.21 million in cash. This high-cost financing underscores the company's inability to secure traditional debt or equity capital, while ongoing material weaknesses in internal controls further raise governance concerns.
Strategically, the company confirmed the 'Effective Date' of its exclusive license agreement with NeoImmuneTech (NIT) for U.S. and Canadian rights to Endari. While this deal provides an upfront fee and potential royalties, NIT lacks commercial experience, and the agreement includes performance hurdles that could revert rights back to Emmaus if NIT fails to meet sales targets by October 2026.
SEC 10-Q • 5mo ago AI analysis › 
